Pharmacogenetics is the study of genetic factors related to human variability in response to medicines. Its modern root lies in the work of Archibald Garrod, whose work on alcaptonuria in 1902 comprised the first proof of Mendel’s laws of genetics in humans.
PHARMACOGENETICS
Pharmacogenetics
is the study of genetic factors related to human variability in response to
medicines. Its modern root lies in the work of Archibald Garrod, whose work on
alcaptonuria in 1902 comprised the first proof of Mendel’s laws of genetics in
humans. Garrod hypothesized that adverse reactions after drug ingestion could
result from genetically determined differences in bio-chemical processes and
further suggested that enzymes play a role in the detoxifi-cation of foreign
substances and that the lack of an enzyme in an individual might cause that
mechanism to fail (Garrod, 1902).
Incidental
clinical observations during the late 1940s and 1950s resulted in the discovery
of several relatively common genetic variations related to ADRs. Hemolysis
related to anti-malarial treatment was much more common among African-American
soldiers during World War II, leading to the identi-fication of inherited
variants of glucose-6-phosphate dehydrogenase (G-6-PD). Prolonged muscle
relax-ation and apnea after suxamethonium was found to be caused by an
inherited deficiency of a plasma cholinesterase. Peripheral neuropathy was
observed in a significant number of patients treated with the anti-tuberculosis
drug isoniazid, leading to the identifica-tion of genetic differences in
acetylation pathways.
The
genetic variations related to these observations are called polymorphisms-inter-individual
differences in DNA sequences at a specific chromosomal loca-tion that exist at
a frequency of more than 1% in the general population. The two alleles (alternate forms of a gene)
present at a given gene locus comprise the genotype,
which now can be characterized at the DNA
level. The progress of The Human Genome Project and advances in genomic
technology enhance the like-lihood that genetic markers that predict a
percent-age of adverse events, including lack of efficacy will be identified,
validated and offered to the public in the next 5–10 years.
The
influence of genotype on phenotype
(observ-able features resulting from the action of one or more genes) – in this
case, the influence of genes on drug kinetics or dynamics – now can be measured
using advanced analytical methods for metabolite detec-tion and clinical
investigation tools such as receptor-density studies by positron emission
tomography (Meyer, 2000).
The
FDA approved the first commercially available kit to measure some P450
polymorphisms in 2004, thus moving the delivery of genetic tests that can
affect drug response to be more readily available to clinical practice.
Pharmacogenetic mechanisms related to polymor-phisms can result in clinically relevant sequelae in at least three ways:
• through
genes associated with altered drug metabolism and transport: increased or
decreased metabolism of a drug can affect the concentration of the drug and its
active, inactive and toxic metabo-lites (e.g. metabolism of tricyclic
anti-depressants),
• through
genes associated with unexpected drug effects (e.g. haemolysis in G-6-PD
deficiency) and
• through
genes associated with genetic variation in
drug targets, resulting
in altered clinical response and
frequency of ADRs
(e.g. 2-adrenergic receptor
variants and altered response to 3-agonists in asthmatic patients) (Meyer,
2000).
Inherited variations related to
drug metabolism generally are monogenic (single gene) traits, and their
clinical relevance in terms of pharmacokinetics and dynamics depends on their
importance for the acti- vation or inactivation of drug substrates (Evans and
Relling, 1999). The most important effects include toxicity for medicines that
have a narrow therapeu- tic window and are inactivated by a polymorphic enzyme
(e.g. thioguanine, flourouracil, mercaptop- urine and azathioprine) and
decreased efficacy of medicines that require activation by an enzyme that
exhibits a polymorphism (e.g. codeine). These vari- ant genes and the enzymes
they code for also may be involved in some drug–drug interactions. Most of
these monogenic traits have been identified on the basis of dramatic observed
differences in response (efficacy and toxicity) among individuals. Although
still not in common clinical use, functional enzyme analyses or genotyping to
detect some of the common monogenic traits affecting drug metabolism are begin-
ning to be used more frequently, especially in the field of cancer chemotherapy
(Iyer and Ratain, 1998; Mancinelli, Cronin and Sadee, 2000).
The FDA has begun to include more
pharmacoge- netic data into the drug labels of medicines. Accord- ing to Dr.
Larry Lesko, 35% of all drugs have some pharmacogenetic data included in their
drug label. In 2003–04, the labels of several medicines were modified to reflect
the risks associated with certain genotypes. Azathioprine, 6-mercaptopurine,
thiogua- nine and irinotecan have information about genotype effects on drug
safety in their labels. Thioridazine has a black box warning related to P450
2D6 poor metab- olizers. Strattera, a drug for attention deficit hyperac-
tivity disorder also lists the drug–genotype interaction prominently in its
drug label.
Although these monogenic traits
affecting drug metabolism are important, the overall pharmacologic effects of
drugs are more likely to be related to the interaction of several genes (polygenic), all encod- ing proteins that are involved in multiple pathways of
metabolism, transport, disposition and action (Evans and Relling, 1999). These
polygenic traits, which also may play a role in drug–drug interactions, are
more challenging to uncover during clinical trials, espe- cially when the
mechanisms of drug metabolism and action are unknown. In contrast with the
past, when clinical observations of individual differences in drug response
prompted biochemical and genetic research into the underlying causes, recent
advances in molec- ular sequencing technology may reverse that process:
laboratory identification of polymorphisms (espe- cially those in gene
regulatory or coding regions) may be the initiating observation, followed by
biochemical and human studies to ascertain their phenotypic and clinical
consequences (Evans and Relling, 1999).
Continued research in
pharmacogenetics has the potential to result in the elucidation of the genetic
basis of drug metabolism, disposition and response. In some cases, the results
of research may provide clinicians with the ability to subclassify patients
using pharmacogenetic-based diagnostic criteria. If research efforts are
successful, then it will become possible, in many circumstances, to select
medicines and deter- mine appropriate dosing on the basis of an individual
patient’s inherited ability to metabolize and respond to specific drugs, thus
reducing the enormous individ- ual, societal and economic burdens currently
related to treatment failures and ADRS.
The US National Institute of
General Medical Sciences (NIGMS) and other components of the National
Institutes of Health (NIH) are sponsoring a major research initiative, the
Pharmacogenetics Research Network, to reach this goal. This network,
established in 2000, initially comprised nine teams of investigators across the
United States, with research projects including asthma treatments, tamoxifen
and other cancer drugs, ethnic differences in response to anti-depressants,
drug transporters, database design and ethical, legal and social ramifications
of pharmacogenetic research (http://www.nigms.nih.gov/
PGRN.Network/Pharmacogeneticworkinggroup.htm).
Related Topics
TH 2019 - 2024 pharmacy180.com; Developed by Therithal info.